Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MorphoSys has received a clinical milestone payment from Centocor Ortho Biotech in connection with the regulatory filing of a clinical trial application for a Phase 1 clinical trial of a HuCAL-derived antibody in the therapeutic area of inflammatory and autoimmune diseases.
Subscribe to our email newsletter
MorphoSys’s clinical pipeline now comprises nine partnered programs in Phase 1 and five in Phase 2 development as well as the company’s proprietary programs MOR103, which is in a Phase 1b/2a trial for rheumatoid arthritis, and MOR208, which is in a Phase 1 trial for chronic lymphocytic leukemia.
MorphoSys chief scientific officer Marlies Sproll said that the seventh clinical milestone with partners in 2010 surpasses their original expectations for the year of up to six such events.
"Today’s news marks another milestone for the HuCAL platform, clearly illustrating the success of this technology," Sproll said.